Provided by Tiger Trade Technology Pte. Ltd.

Denali Therapeutics Inc.

19.69
-0.0100-0.05%
Post-market: 19.760.0700+0.36%19:34 EST
Volume:1.26M
Turnover:24.54M
Market Cap:3.12B
PE:-6.63
High:19.76
Open:19.46
Low:19.05
Close:19.70
52wk High:23.77
52wk Low:10.57
Shares:158.59M
Float Shares:144.00M
Volume Ratio:0.91
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9700
EPS(LYR):-2.9700
ROE:-45.69%
ROA:-27.56%
PB:3.08
PE(LYR):-6.63

Loading ...

Denali Therapeutics reports $872.9 million cash position ahead of key 2026 milestones

Reuters
·
Jan 06

Denali Therapeutics Inc - FDA Lifts Clinical Hold on Dnl952, Phase 1 Study to Proceed

THOMSON REUTERS
·
Jan 06

Denali Therapeutics Inc - Prepares for FDA Approval and Launch of Tividenofusp Alfa

THOMSON REUTERS
·
Jan 06

Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

GlobeNewswire
·
Jan 06

Denali Therapeutics Reports Positive Phase 1/2 Results for Tividenofusp Alfa in Hunter Syndrome

Reuters
·
Dec 30, 2025

Does Denali’s $200M Equity Raise And FDA Talks Change The Bull Case For DNLI?

Simply Wall St.
·
Dec 24, 2025

Does Denali Therapeutics' (DNLI) Discounted Equity Raise Reveal a New Phase in Its Risk Strategy?

Simply Wall St.
·
Dec 17, 2025

Denali Therapeutics Shares Fall in Premarket on Share Offering Price

Dow Jones
·
Dec 10, 2025

BRIEF-Denali Therapeutics Says Co Prices Public Offering Of 9.14 Mln Shares At $17.50 Each

Reuters
·
Dec 10, 2025

Denali Therapeutics Inc - Prices Public Offering of 9,142,857 Shares at $17.50 Each

THOMSON REUTERS
·
Dec 10, 2025

BUZZ-Denali Therapeutics slides after launching $200 million share sale

Reuters
·
Dec 10, 2025

Denali Therapeutics: to Offer & Sell $200 Mln of Shares of Its Common Stock and, in Lieu of Common Stock to Certain Investors, Warrants

THOMSON REUTERS
·
Dec 10, 2025

Denali Therapeutics Inc - Grants Underwriters Option for $30 Mln Additional Shares

THOMSON REUTERS
·
Dec 10, 2025

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire
·
Dec 10, 2025

Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start

Benzinga_recent_news
·
Dec 06, 2025

Denali Therapeutics, Royalty Pharma Enter $275 Million Royalty Funding Agreement for Hunter Syndrome Treatment

Dow Jones
·
Dec 04, 2025

Denali Therapeutics Inc - Royalty Pharma to Receive 9.25% Royalty on Worldwide Sales of Tividenofusp Alfa From Denali

THOMSON REUTERS
·
Dec 04, 2025

Press Release: Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Dow Jones
·
Dec 04, 2025

Denali Therapeutics Drops Amid Volume Surge, Last Down 6.3%

THOMSON REUTERS
·
Dec 02, 2025

Denali Therapeutics Q3 Operating Expenses USD 137.434 Million

Reuters
·
Nov 20, 2025